"Intermountain launches groundbreaking study using the PreTRM test to prevent preterm birth." Read more here


"Women want good information. If a test predicts that they might have a preterm birth, they want to know."


PreTRM Test Featured in Top-Tiered Scientific Journal as Example of Proteomic Test That Advances Patient Care. Read More


"The value of the PreTRM test cannot be overestimated. We continue to deal with the vast majority of women who eventually go into preterm labor and deliver early with having absolutely no identifiable risk factors." Watch Dr. Shulman's video here


“We developed a novel blood test to PREDICT, at an EARLY point in pregnancy, a woman’s individual risk of having a premature baby. We aim to achieve our vision of improving the health of newborns by enabling earlier, effective interventions that make a difference.” Dr. Greg Critchfield, CEO


"With 1 in 10 women in the United States delivering prematurely, I believe every woman is an excellent candidate for the PreTRM test." Watch Dr. Mandel's video here


Sera Prognostics Receives New York State Approval for PreTRM® Testing

Dec. 12, 2018 -- Sera Prognostics, The Pregnancy Company(™), announced that the New York State Department of Health has issued a clinical laboratory permit for Sera to perform PreTRM® testing for pregnant women in the state of New York. The lab approval was based on the results of an on-site inspection and rigorous evaluation process. With this approval, Sera can now commercialize the PreTRM® test in New York, a very important health care market. Read More >

Sera Prognostics Completes Enrollment of Large, Multicenter, Prospective Clinical Study of PreTRM® Test

Nov. 27, 2018 -- Sera Prognostics, The Pregnancy Company(™), announces that it has completed enrollment of 5,009 women into its prospective real-time study, “A Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor (TREETOP).” Read More >

Intermountain Health and Christiana Care Health System Begin Enrollment on Two Landmark Preterm Birth Studies with PreTRM® Test

July 1, 2018 - Sera Prognostics®, The Pregnancy Company™, announces the recent launch of two new preterm birth studies using the PreTRM® test to identify high-risk mothers for intervention care. Read More >


Our Goals

Providing An Individualized Risk Assessment to Predict and Manage premature birth, preeclampsia, and other Pregnancy Complications

Sera Prognostics is focused on improving maternal and infant health by developing simple blood tests to predict the risks of pregnancy complications. Our initial focus is on one of the most serious pregnancy complications—preterm birth—which affects 9.6% of pregnancies in the U.S. alone.

Early and accurate prediction of risk for pregnancy complications may help pregnant women and their doctors take action and make a difference by putting early interventions in place. Learn about the PreTRM® Test for Risk Management.